Mergers & Acquisitions ·
Centessa Pharmaceuticals plc completed an acquisition by Eli Lilly and Company via a court-sanctioned scheme of…
CNTACentessa Pharmaceuticals plc
Centessa Pharmaceuticals plc completed an acquisition by Eli Lilly and Company via a court-sanctioned scheme of arrangement, making it a wholly owned subsidiary of Lilly. Shareholders of Centessa were entitled to receive $38.00 in cash per share plus one non-transferable contingent value right (CVR) entitling them to receive up to $9.00 per share in contingent cash payments based on milestones. The company's Nasdaq delisting and termination of its existing loan and security agreement were also part of the transaction. Centessa Pharmaceuticals plc is a biotechnology company focused on developing clinical-stage therapeutic solutions.